News Search Results
May 30, 2025, 08:00 ET Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced the closing of a $20
More news about: Diakonos Oncology
May 30, 2025, 08:00 ET BIOVAXYS ANNOUNCES CONSOLIDATION AND CONCURRENT BROKERED PRIVATE PLACEMENT OFFERING FOR GROSS PROCEEDS OF UP TO $3,000,000
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
May 30, 2025, 06:32 ET Weekly Recap: 14 Health Press Releases You Need to See
UniXell Biotechnology announces the first patient dosed with UX-DA001, an investigational autologous iPSC based cell therapy for the treatment of Parkinson's Disease,
More news about: PR Newswire
May 30, 2025, 03:01 ET Highlights of ESHG | Rapid AI Karyotype Total Solution From China Makes a Big Splash
conference of the European Society of Human Genetics (ESHG) 2025 held successfully in Milan, Italy. Hangzhou Diagens Biotechnology Co., Ltd. (www.diagens.com) from China, made
More news about: Diagens Biotechnology
May 29, 2025, 21:32 ET Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
limited time following the event. About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We
More news about: Kodiak Sciences Inc.
May 29, 2025, 20:40 ET BioVaxys and Horizon Technology Finance Corp Execute Amendment to Asset Purchase Agreement ("APA")
acquiring the entire portfolio of assets and intellectual property based on the DPX™ immune educating platform technology developed by Canadian biotechnology company, IMV Inc.
More news about: BioVaxys Technology Corp.
May 29, 2025, 17:31 ET Anal Cancer Market Heats Up Following Incyte's Zynyz Greenlight | DelveInsight
companies, including Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, among
More news about: DelveInsight Business Research, LLP
May 29, 2025, 17:00 ET Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 29, 2025, 16:30 ET Amyris Takes Full Ownership of Brazilian Industrial Fermentation Plant and Invests in Completion of Fourth Precision Fermentation Line
2025 /PRNewswire/ -- Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, today announced that it has acquired Ingredion's 31% stake in the RealSweet Joint Venture to take full ownership of the industrial precision fermentation
More news about: Amyris, Inc.
May 29, 2025, 16:30 ET Amyris and Ingredion Wind Down RealSweet Joint Venture
2025 /PRNewswire/ -- Amyris, Inc., a vertically integrated synthetic biology company and leading innovator in the field of industrial biotechnology, and Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food manufacturing industry, today announced
More news about: Amyris, Inc.
May 29, 2025, 14:28 ET RevivBio Welcomes Dr. Ronald Meeusen to Board of Directors, Strengthening Leadership in Biotech Innovation and Commercialization
Biosensors development, welcomes Dr. Ron Meeusen to its Board of Directors. Dr. Meeusen is a renowned leader in biotechnology, with a distinguished track record of developing and commercializing world-changing innovations across food, agricultural biotech, and therapeutics.
More news about: RevivBio
May 29, 2025, 13:12 ET Kalorama Information Releases 12th Edition of Global Point-of-Care Diagnostics Market Report, Forecasting Steady Growth Through 2029 for $36 Billion POC Market
InformationKalorama Information, a division of Science and Medicine Group, is a leading independent market research publisher in medical diagnostics, biotechnology, and life sciences. Our in-depth reports offer actionable insights to support critical business decisions for healthcare companies, investors, and
More news about: Kalorama Information
May 29, 2025, 12:00 ET Globee® Awards for Technology Invites Industry Experts from Around the World to Participate as Judges
technology, digital transformation, EdTech, emerging and niche technologies, enterprise technology, fintech, blockchain, InsureTech, healthcare, biotechnology, sports tech, immersive tech and AR/VR, industry-based technologies, information technology, MarTech, software, specialized and breakthrough technologies,
More news about: Globee Awards
May 29, 2025, 12:00 ET Miller Children's & Women's Hospital Contributes to Landmark Study Transforming Pediatric Leukemia Treatment
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Miller Children’s & Women’s Hospital
May 29, 2025, 10:30 ET Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR | MarketsandMarkets™
segmented into pharmaceutical & biotechnology companies, contract service organizations, biobanks & biorepositories, clinical research laboratories, academic research institutes, NGS laboratories, and toxicology laboratories. In 2024, the pharmaceutical & biotechnology companies segment accounted
More news about: MarketsandMarkets
May 29, 2025, 09:00 ET Made Scientific Powers Late-Phase and Commercial Cell Therapy Manufacturing with 12,000 sq. ft. Expansion in Princeton, NJ GMP Facility
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For more information: [email protected] or follow Made
More news about: Made Scientific, Inc.
May 29, 2025, 09:00 ET Pvolve and Tally Health Partner to Advance Longevity Through Smarter Movement and Scientific Insight
ealth, a revolutionary consumer-facing biotechnology company aimed at improving healthspan and longevity, to deliver a one-of-a-kind, preventive health journey designed to elevate every aspect of well-being
More news about: Pvolve
May 29, 2025, 08:30 ET Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting
SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts
More news about: Grit Biotechnology
May 29, 2025, 08:00 ET Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced that it will present new clinical
More news about: Diakonos Oncology
May 29, 2025, 08:00 ET Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
May 29, 2025, 08:00 ET AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
meaningful therapeutic effect on the disease. About AccurEdit Therapeutics AccurEdit Therapeutics, founded in 2021, is a biotechnology company focused on developing in vivo gene editing technologies and therapies based on lipid nanoparticle (LNP) and other non-viral delivery systems.
More news about: AccurEdit Therapeutics
May 29, 2025, 07:05 ET Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
May 29, 2025, 06:55 ET ETFs Unlock Growth in China's Booming Tech Landscape
infrastructure.Healthcare TechnologyGene-editing technologies are poised to revolutionize treatments for genetic disorders and cancer. The E Fund CSI Biotechnology ETF (159837) invests in companies specializing in gene diagnostics, biopharmaceuticals, and advanced biomedical research, positioning it at the
More news about: E Fund Management
May 29, 2025, 06:47 ET ETFs Unlock Growth in China's Booming Tech Landscape
infrastructure.Healthcare TechnologyGene-editing technologies are poised to revolutionize treatments for genetic disorders and cancer. The E Fund CSI Biotechnology ETF (159837) invests in companies specializing in gene diagnostics, biopharmaceuticals, and advanced biomedical research, positioning it at the
More news about: E Fund Management
May 29, 2025, 06:00 ET Stealth BioTherapeutics Announces "Path Forward" Despite Disappointing Delay for Ultra-rare Barth Syndrome
May 29, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.